• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    G1 Therapeutics, Inc. - Common Stock (NQ: GTHX )

    7.150 UNCHANGED
    Last Price Updated: 4:00 PM EDT, Sep 17, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 7.150
    Bid (Size) 7.140 (212)
    Ask (Size) 7.180 (13)
    Prev. Close 7.150
    Today's Range 7.150 - 7.150
    52wk Range 1.442 - 7.190
    Shares Outstanding 42,705,532
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer
    From G1 Therapeutics
    Via GlobeNewswire
    Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period
    From G1 Therapeutics
    Via GlobeNewswire

    Performance

    YTD
    +129.90%
    +129.90%
    1 Month
    N/A
    N/A
    3 Month
    N/A
    N/A
    6 Month
    +213.60%
    +213.60%
    1 Year
    +135.97%
    +135.97%

    More News

    Read More
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GVP, PETQ, GTHX on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    Why Is G1 Therapeutics (GTHX) Stock Up 66% Today?
    Via InvestorPlace
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Thoughtworks Holding, Inc. (Nasdaq – TWKS), PetIQ, Inc. (Nasdaq – PETQ), G1 Therapeutics, Inc. (Nasdaq – GTHX), GSE Solutions, Inc. (Nasdaq – GVP)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    G1 THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of G1 Therapeutics, Inc. - GTHX
    From Kahn Swick & Foti, LLC
    Via Business Wire
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, PETQ on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Thoughtworks Holding, Inc. (Nasdaq – TWKS), PetIQ, Inc. (Nasdaq – PETQ), G1 Therapeutics, Inc. (Nasdaq – GTHX), GSE Solutions, Inc. (Nasdaq – GVP)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
    From G1 Therapeutics
    Via GlobeNewswire
    Dow Tumbles Over 200 Points; CVS Health Cuts Profit Forecast
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Crude Oil Jumps Over 3%; Upstart Shares Spike Higher
    Via Benzinga
    Exposures Fossil Fuels
    Nasdaq Jumps 250 Points; Disney Earnings Beat Estimates
    Via Benzinga
    Topics Earnings
    Exposures Financial
    GTHX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of G1 Therapeutics, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    Pharmacosmos Group to Acquire G1 Therapeutics
    From G1 Therapeutics; Pharmacosmos
    Via GlobeNewswire
    G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
    From G1 Therapeutics
    Via GlobeNewswire
    G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025
    Via InvestorPlace
    Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble
    Via InvestorPlace
    Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday
    Via Benzinga
    Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears
    Via InvestorPlace
    Exposures Product Safety
    Ginkgo Bioworks Layoffs 2024: What to Know About the Latest DNA Job Cuts
    Via InvestorPlace
    Topics Workforce
    Exposures Layoff
    Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
    Via Benzinga
    Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday?
    Via Benzinga
    Why Is G1 Therapeutics (GTHX) Stock Down 56% Today?
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    Via InvestorPlace
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.